Greenwich LifeSciences, Inc.

GLSI

US3968791083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:21:53 2024-07-17 pm EDT			5-day change	1st Jan Change
16.2 ^USD	+2.44%		+1.46%	+52.09%

Jul. 01	Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell Small Cap Completeness Index	CI
Jul. 01	Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2000 Index	CI

Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell Small Cap Completeness Index

July 30, 2024

Latest news about Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell Small Cap Completeness Index	Jun. 30	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2000 Index	Jun. 30	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 3000E Index	Jun. 30	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 3000 Growth Index	Jun. 30	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 3000E Growth Index	Jun. 30	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2000 Growth Index	Jun. 30	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2000 Dynamic Index	Jun. 30	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2500 Growth Index	Jun. 30	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2500 Index	Jun. 30	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 3000 Index	Jun. 30	CI
Greenwich LifeSciences to Join Russell 2000 Index; Shares Rise	Jun. 26	MT
Greenwich Lifesciences Insider Bought Shares Worth $2,499,998, According to a Recent SEC Filing	Jun. 17	MT
Greenwich LifeSciences' CEO Acquires $2.5 Million in Shares	Jun. 14	MT
Greenwich LifeSciences, Inc. announced that it expects to receive $2.499998 million in funding	Jun. 12	CI
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 20	CI
Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing	Mar. 07	MT
Greenwich LifeSciences Secures Approval to Expand GLSI-100's Phase 3 Trial to Europe	Feb. 22	MT
Greenwich Lifesciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators	Feb. 22	CI
HC Wainwright Adjusts Greenwich LifeSciences Price Target to $36 From $38, Maintains Buy Rating	Feb. 20	MT
Greenwich LifeSciences, Inc. Provides Update on Phase III Clinical Trial, Flamingo-01	Feb. 14	CI
Sector Update: Health Care Stocks Rise in Afternoon Trading	Feb. 14	MT
Greenwich LifeSciences Shares Surge on Planned Regulatory Filing of Breast Cancer Treatment	Feb. 14	MT

Chart Greenwich LifeSciences, Inc.

Duration

Period

More charts

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.81 USD

Average target price

36 USD

Spread / Average Target

+127.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GREENWICH LIFESCIENCES, INC.	+52.09%	204M
CSL LIMITED	+7.46%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+11.97%	42.34B
BIOGEN INC.	-11.49%	32.76B
UCB	+79.34%	29.46B
BIOMARIN PHARMACEUTICAL INC.	-12.50%	16.31B
INCYTE CORPORATION	+3.45%	14.39B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.90%	12.23B
ALTEOGEN INC.	+178.17%	10.47B
SWEDISH ORPHAN BIOVITRUM AB	+1.80%	8.97B

Biopharmaceuticals